SYF - SYF シンクロニ―・ファイナンシャル （）

Building on a nearly 20-year relationship, the companies will leverage advanced insights and technology to drive consumer demand and growth MINNEAPOLIS and STAMFORD, Conn. , Sept. 1, 2022 /PRNewswire/ -- Synchrony (NYSE: SYF ) and Sleep Number (NASDAQ: SNBR ) announced that they have renewed their longtime financing partnership, which includes new joint investments from both industry leaders. Their commitment will continue to focus on exceptional customer experiences and make Sleep Number''s award-winning sleep and wellness solutions attainable for more consumers. The multi-year agreement deepens the two companies'' nearly 20-year relationship and draws on their trajectory of innovation in their respective industries. To build upon their success, new areas of collaboration are planned to include: Investing in advancements, including consumer payment choices; Deepening personalization; and Increasing customers'' access to credit. "Together, our companies have developed a strong team and deep understanding of how payment experiences drive customer satisfaction and business growth at Sleep Number," said Curtis Howse , CEO of Home and Auto, Synchrony. "We share a passion for innovation and digital reinvention and have built a terrific foundation for what comes next: creating an enhanced customer experience that utilizes more customer and credit insights, combined with the significant advancements we''ve made in payments.

Synchrony Financial (NYSE:SYF) traded at $32.85 at last check on Monday, August 29, made a downward move of -2.36% on its previous day’s price. Looking at the stock we see that its previous close was $33.65 and the beta (5Y monthly) reads 1.57 with the day’s price range being $33.64 – $35.365. The company has … Synchrony Financial (NYSE:SYF) Slides -2.36 Percent In Recent Trade, What Can We Expect Next? Read More »

Synchrony Financial (SYF) credit card delinquency and net charge-off rates both rose in July as credit quality gradually normalizes from the unusually low levels experienced during…

Synchrony Financial found using ticker (SYF) have now 19 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 65 and 22 with a mean TP of 42.05. Given that the stocks previous close was at 36.11 this would indicate that there is a potential upside of 16.4%. The day 50 moving average is 31.82 and the 200 day MA is 39.47. The market cap for the company is $17,411m. You can visit the company''s website by visiting: https://www.synchrony.com [stock_market_widget type="chart" template="basic" color="green" assets="SYF" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $20,275m based on the market concensus. Synchrony Financial, together with its subsidiaries, operates as a consumer financial services company in the United States. It provides credit products, such as credit cards, commercial credit products, and consumer installment loans. The company also offers private label credit cards, dual cards, co-brand and general purpose credit cards, short- and long-term installment loans, and consumer banking products; and deposit products, including certificates of deposit, individual retirement accounts, money market accounts, and savings accounts to retail and commercial customers, as well as accepts deposits through third-party securities brokerage firms.

In recent trading session, Synchrony Financial (NYSE:SYF) saw 0.66 million shares changing hands at last check today with its beta currently measuring 1.57. Company’s recent per share price level of $35.84 trading at -$0.27 or -0.75% at last check today assigns it a market valuation of $17.32B. That most recent trading price of SYF’s stock … Synchrony Financial (NYSE:SYF) Shares Rebounded 24.05% From Their Lows – But Can They Continue? Read More »

Synchrony Financial (NYSE:SYF) has a beta value of 1.52 and has seen 0.96 million shares traded in the recent trading session. The company, currently valued at $13.87B, closed the recent trade at $28.68 per share which meant it lost -$0.28 on the day or -0.97% during that session. The SYF stock price is -83.02% off … Synchrony Financial (SYF) Has Strong Growth Prospects Through 2022 Read More »

Citi on Wednesday has added Synchrony Financial (SYF) to its Focus List with a Buy rating on the basis of a favorable risk-reward setup as recession fears get priced into credit…

Someone with a lot of money to spend has taken a bullish stance on Synchrony Finl (NYSE: SYF ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with SYF, it often means somebody knows something is about to happen. Today, Benzinga''s options scanner spotted 15 options trades for Synchrony Finl. This isn''t normal. The overall sentiment of these big-money traders is split between 53% bullish and 46%, bearish. Out of all of the options we uncovered, 14 are puts, for … Full story available on Benzinga.com

Synchrony Financial''s (SYF) credit card adjusted net charge-off rate increased in May from April, but it''s still well below the year-ago level.Lending activity increased in May,…

Synchrony Financial (NYSE:SYF) has a beta value of 1.44 and has seen 1.15 million shares traded in the recent trading session. The company, currently valued at $18.34B, closed the recent trade at $35.72 per share which meant it lost -$0.07 on the day or -0.18% during that session. The SYF stock price is -46.95% off … Why Do Investors Buy Stock In Synchrony Financial (SYF)? Read More »

Piper Sandler analyst Kevin Barker raised his call on the credit-card stock to Overweight from Neutral, citing credit quality, among other factors.

Upgrades According to Morgan Stanley, the prior rating for Royalty Pharma PLC (NASDAQ: RPRX ) was changed from Equal-Weight to Overweight. In the fourth quarter, Royalty Pharma showed an EPS of $0.80, compared to $0.27 from the year-ago quarter. The current stock performance of Royalty Pharma shows a 52-week-high of $47.10 and a 52-week-low of $34.86. Moreover, at the end of the last trading period, the closing price was at $39.84. According to Keefe, Bruyette & Woods, the prior rating for PJT Partners Inc (NYSE: PJT ) was changed from Market Perform to Outperform. PJT Partners earned $1.52 in the fourth quarter, compared to $1.81 in the year-ago quarter. At the moment, the stock has a 52-week-high of $89.50 and a 52-week-low of $54.48. PJT Partners closed at $63.06 at the end of the last trading period. Guggenheim upgraded the previous rating for Array Technologies Inc (NASDAQ: ARRY ) from Neutral to Buy. Array Technologies earned $0.06 in the fourth quarter, compared to $0.08 in the year-ago quarter.

Investors are failing to take note of positive trends, such as strong credit performance, from the credit card provider, analysts say.

PayPal Holdings <> has unveiled a new cashback credit card, issued by Synchrony Financial <>, that rewards customers 3% cash back when they pay with PayPal at checkout…

The store-card issuer had a strong fourth quarter, but inflation and economic concerns took their toll.